drug eluting stent☆Everolimus and its pharmacologic counterparts (eg, sirolimus, zotarolimus) are cytostatic drugs that inhibit mTOR (mammalian target of rapamycin receptor), blocking the cell cycle between the G1 and S phase to reduce smooth muscle cell proliferation.
Coating the intracoronary stent surface with an antiproliferative agent such as everolimus creates a drug-eluting stent that helps ☆prevent neointimal hyperplasia and stent restenosis. cardiologypharmacologyUWorld SIM2 HirotoShishido
congenital heart defect in the patient with congenital rubella syndrome(SRS)PDA>PS, VSD, ASD
the strongest risk factor for coronary heart diseasehighest→ ☆diabetes mellitus, noncoronary atherosclerotic disease, CKD
other major risk factors→ HTN, hyperlipidemia, smoking, ↑age, obesity, physical inactivity
Several studies have shown that diabetes mellitus is one of the strongest risk factors for coronary heart disease.
The risk of dying from coronary heart disease exceeds the risk of dying from any of the other listed causes, even in the absence of other major risk factors forcoronary heart disease. cardiologyUWorld HirotoShishido
drugs which has been shown to improve long-term survival in patients with HF due to left ventricular systolic dysfunctionβ-blocker(Bisoprolol, ☆Carvedilol, Metoprolol (β-blockers Curb Mortality)),
ACE inhibitors, ARB, aldosterone antagonists cardiologypharmacologyUWorld HirotoShishido
